UK-based Ignota Labs has acquired all of the clinical-stage assets in Kronos Bio's pipeline, after the US company ceased operations earlier this year. Ignota specialises in turning around promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback